Analysts suggest investors buy Merck & Co., Inc. stock during a current price dip to $114.90 [1].
This recommendation comes as the pharmaceutical leader balances a significant one-time acquisition cost against steady dividend growth and a low valuation. For investors, the dip represents a potential entry point into a company with strong yield prospects despite temporary earnings volatility.
Merck, listed on the New York Stock Exchange under the ticker MRK [1], recently reported its Q1 2026 earnings. The report was dominated by a $9 billion acquisition charge related to Cidara [2]. This substantial cost created a temporary hit to the company's reported earnings for the period.
Despite the acquisition charge, market analysts point to the company's fundamental valuation as a primary draw. The stock currently offers a 3% dividend yield [1]. Furthermore, the forward price-to-earnings ratio stands at 12x [1].
"Merck looks like a buy‑the‑dip at $114.90 with a 3% yield and 12x forward P/E," the author of a Seeking Alpha report said [1].
The strategy for buying the dip relies on the belief that the $9 billion charge is a non-recurring event [2]. Because the cost is tied to a specific acquisition, it does not reflect the long-term operational health, or the recurring revenue streams, of the pharmaceutical giant.
Investors often look for these types of temporary dislocations in price to acquire shares of dividend-growth leaders at a discount. With a forward P/E of 12x [1], the stock is priced lower than many of its peers in the healthcare sector, making it an attractive option for value-oriented portfolios.
“Merck looks like a buy‑the‑dip at $114.90 with a 3% yield and 12x forward P/E.”
The recommendation to 'buy the dip' suggests that the market may have overreacted to the $9 billion acquisition charge in the Q1 2026 report. By focusing on the 12x forward P/E and 3% dividend yield, analysts are arguing that Merck's long-term value is decoupled from the temporary accounting hit of the Cidara acquisition, positioning the stock as a value play in the pharmaceutical sector.
